SMOLDERING PLASMA CELL MYELOMA
Clinical trials for SMOLDERING PLASMA CELL MYELOMA explained in plain language.
Never miss a new study
Get alerted when new SMOLDERING PLASMA CELL MYELOMA trials appear
Sign up with your email to follow new studies for SMOLDERING PLASMA CELL MYELOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could an immune drug slow down multiple myeloma before it starts?
Disease control OngoingThis phase 2 trial tests whether leflunomide, a drug that calms the immune system, can delay the start of multiple myeloma in people with high-risk smoldering multiple myeloma. The study includes 27 African-American and European-American participants. Researchers are tracking how…
Matched conditions: SMOLDERING PLASMA CELL MYELOMA
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 17, 2026 04:15 UTC
-
Could an arthritis drug delay blood cancer?
Disease control OngoingThis early-phase trial tests leflunomide, an anti-inflammatory drug, in patients with high-risk smoldering multiple myeloma. The goal is to see if it can delay progression to active myeloma. Only one person enrolled, so results are very limited.
Matched conditions: SMOLDERING PLASMA CELL MYELOMA
Phase: EARLY_PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
Promising drug combo aims to stall Early-Stage blood cancer
Disease control OngoingThis study tests a drug called isatuximab, given alone or with lenalidomide, in 61 people with high risk smoldering multiple myeloma—a condition that often leads to active cancer. The goal is to see if the treatment can shrink or control the disease and delay progression. Partici…
Matched conditions: SMOLDERING PLASMA CELL MYELOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 13, 2026 16:04 UTC
-
Early trial aims to stop 'Smoldering' cancer before it ignites
Disease control OngoingThis small, early-stage study is testing whether the immunotherapy drug pembrolizumab can help control or delay the progression of smoldering multiple myeloma, a slow-growing precursor to an aggressive bone marrow cancer. The trial involves 20 adults with intermediate or high-ris…
Matched conditions: SMOLDERING PLASMA CELL MYELOMA
Phase: EARLY_PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 06, 2026 14:15 UTC